Innovation that Matters

Filter By


WuXi Partners with QB3 on its New Incubator in San Francisco

WuXi is partnering with QB3 on its new incubator in San Francisco. The 24,000-square foot biosciences incubator is the latest expansion of the highly-successful QB3 program, which supports entrepreneurs with cutting-edge science. We sat down with Associate Director of QB3 and General Manager of QB3 Partners, Douglas Crawford, to talk about the partnership and expansion. QUESTION: Can you provide some background on QB3 and what you do? CRAWFORD: QB3 was set up in 2000 to foster the development of innovative startups. We do this in a variety of ways, but I’d single out two as being particularly important. Firstly, our industry partners help QB3 startups identify technical risks, which is a big challenge for young companies. And secondly, we help finance research through our venture fund, Mission Bay Capital. We’re really pleased to have WuXi’s support in both these areas. QUESTION: How does the new expansion help you further this mission? CRAWFORD: It gives us more space! We already have two facilities near the UCSF Mission Bay campus, and another two in Berkeley, but to support more great science we need another site. At 24,000-square foot the new incubator, QB3@953, is our biggest yet. When we’re at capacity we expect to house up to 30 startups. Ultimately, that means we’re supporting a lot more innovative work than we could before. QUESTION: How has your experience with earlier incubators shaped QB3@953? CRAWFORD: We’ve become even more focused on helping startups make the most of every dollar. So, entrepreneurs can start by renting just one bench, and then pay for space in super-freezers or use of centrifuges as and when they need to. It’s about flexibility, really. And we try to leverage collective scale to lower costs and simplify logistics too. Lab gloves are dispensed centrally, for example. Anything that frees up great researchers to focus on doing innovative science is a good thing. Related Links: QB3 to Collaborate with Johnson & Johnson Innovation on New Incubator (Source: The Wall Street Journal) QB3, partnership to open new, large life sciences incubator (Source: San Francisco Business Times)

Read more


An Interview with Dr. Lawson Macartney, CEO of Ambrx Pharmaceuticals

An interview with Dr. Lawson Macartney, CEO of Ambrx Pharmaceuticals, on the co-development of an ADC therapeutic for HER2-Positive breast for cancer in China.   THE NEWS: This month’s Inside Perspective features Dr. Lawson Macartney, CEO of Ambrx Pharmaceuticals. Ambrx recently announced a deal in which it would co-development a therapeutic for HER2-positive breast cancer with China-based Zhejian Medicine Co. WuXi will handle preclinical, clinical trials and toxin manufacturing. ZMC will hold commercial rights to the compound in China, Ambrx holds rights in the rest of the world, collecting royalties on Chinese sales. QUESTION: Ambrx has an industry-leading ADC technology platform and a number of notable partnerships with western pharmas like Merck and BMS. Why the expansion into China?   Macartney: Accessing the China market is becoming an increasingly important objective within Ambrx. Developing and manufacturing biologics within China to world class standards is a relatively new paradigm. We look forward to integrating these efforts into our global development strategy. QUESTION:From a business perspective, this three-party deal is very creative and intriguing. Could you explain the strategy?  Macartney: This partnership is unique. It allows us to team up with China’s leading pharmaceutical and CRO companies to efficiently access the China market, an opportunity that we would otherwise miss if we were not to combine our respective efforts. This is an innovative deal structure that allows us to gain access to China while also reducing time and R&D costs. QUESTION: What’s one thing you learned putting together this deal that could benefit other companies looking to develop drugs to sell in China? Macartney: Build strong relationships with those that you do business with. This will better enable the collaborations to overcome obstacles and take advantage of opportunities. Related Links: Expediting Development of Biologics in China: From Strategy to Regulatory Expectations and Beyond Ambrx and Zhejiang Medicine Co. Ltd. Form Collaboration to Develop and Commercialize Ambrx’s Antibody Drug Conjugate for Breast Cancer

Read more


Congratulations to Foundation Medicine for a Successful IPO

Our warm congratulations to Foundation Medicine on the important milestone of initial public offerings! Located in Cambridge, Massachusetts, Foundation Medicine is a cancer diagnostic biotech company that enables doctors to recommend treatment options for cancer patients based on their genetic profile. WuXi Corporate Venture Fund participated in its Series B financing in 2012 to help furthering its mission of transforming cancer care through deeper understanding of the underlying genomic changes. On the first day of its market debut on September 24, Foundation Medicine shares rose as much as 89 percent, raising about $106 million to expand its commercial and laboratory operations, and to fund clinical studies. The strong market response reflects great public confidence in the company’s innovative approaches, and the potential of genomics in the treatment of diseases. Congratulations, and we wish Foundation Medicine continued success in bringing better medicines closer to patients! Related Links:  Steve Jobs’ Final Vision Is Coming True Thanks (In Part) To Bill Gates And Google (Source: Business Insider) Foundation Medicine shares rise 89 percent in market debut (Source: Reuters)  Foundation Medicine Expands Series B Financing to $56 Million

Read more